Study of IMX-110 in Combination With Tislelizumab in Patients With Advanced Solid Tumors

Clinical trial NCT05840835 · UNKNOWN

Trial details

NCT number: NCT05840835
Sponsor: Immix Biopharma, Inc.
Status: UNKNOWN
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Advanced Solid Tumor

Start date: 2023-02-03
Primary completion: 2024-01-24
Enrollment: 60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.